R . Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naíve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract] . J
Search Results
Targeted Strategies in the Treatment of Metastatic Colon Cancer
Diane Reidy and Leonard Saltz
Selecting Targeted Therapies for Patients With Renal Cell Carcinoma
Elizabeth R. Plimack and Gary R. Hudes
endothelial growth factor (VEGF)-directed therapies (sorafenib, sunitinib, pazopanib, and bevacizumab) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus). With such a large number of treatment options, selecting among them for a
Colon Cancer: The New Chronic Disease
Al B. Benson III
(Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in Metastatic CRC Subjects With Wild-Type KRAS Tumors), were further assessed in secondary analyses to include extended RAS testing ( KRAS exons 2, 3, 4; NRAS exons 2, 3
Maintenance Chemotherapy in Non–Small Cell Lung Cancer
Keith D. Eaton and Renato G. Martins
growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Presented by: Joyce F. Liu
benefit from bevacizumab? Is testing for homologous recombination deficiency (HRD)/genomic instability appropriate? What is the role of maintenance therapy with PARP inhibitors? Of note, because the treatment of advanced ovarian cancer is complex and
Oncology Research Program
Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast
Oncology Research Program
Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson III, Alan P. Venook, Mohamed Adam, George Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah Hoffe, Steven Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, Benjamin Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Lisa A. Gurski, Jenna Snedeker, and Frankie Jones
analysis of the FIRE-3 trial (discussed in “ Cetuximab or Panitumumab Versus Bevacizumab in First-line Therapy ,”) has been published. 30 When all RAS ( KRAS/NRAS ) mutations were considered, PFS was significantly worse in patients with RAS -mutant
Management of Recurrent or Metastatic Cervical Cancer
Presented by: Nadeem R. Abu-Rustum
as bevacizumab and pembrolizumab is difficult in this patient population, because bevacizumab and pembrolizumab are not widely available, are expensive, and require specific expertise to be delivered. Despite their improved activity over traditional
HSR21-065: Oncologists’ Perceptions and Utilization of Therapeutic Oncology Biosimilars in the U.S.
Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra
critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic